CHIMERIC ANTIGEN RECEPTOR T CELLS DERIVED FROM IMMUNOENGINEERED PLURIPOTENT STEM CELLS

The invention provides universally acceptable "off-the-shelf" hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to...

Full description

Saved in:
Bibliographic Details
Main Authors DEUSE TOBIAS, SCHREPFER SONJA
Format Patent
LanguageChinese
English
Published 09.04.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention provides universally acceptable "off-the-shelf" hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to treat cancer. 本发明提供了普遍可接受的"现成的"低免疫性多能(HIP)细胞和来源于HIP细胞的低免疫性嵌合抗原受体T(CAR-T)细胞。可将工程化的治疗细胞作为基于细胞的过继免疫疗法施用至受试者以治疗癌症。
Bibliography:Application Number: CN201980056559